MoneyWorks4Me

Glaxosmithkline Pharmaceuticals informs about cessation of director cum CFO

16 Mar 2018 Evaluate

Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that Andrew Aristidou, Executive Director & CFO has ceased to be a Director & CFO of the Company from close of the business hours on 31st December, 2017.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..